clobetasol and Edema

The effects of topical indomethacin and clobetasol propionate on erythema and oedema following low-dose cryotherapy to normal skin were examined using a single-blind technique. Both agents significantly reduced erythema, but neither had a significant effect on oedema. A further, controlled, double-blind study comparing topical indomethacin and inert gel base was performed after cryotherapy to hand warts. In this study, topical indomethacin had no significant effect on post-cryotherapy oedema, erythema, pain or blister formation 48 and 96 h after treatment. Both potent topical steroids and cyclo-oxygenase inhibitors reduce erythema after low-dose cryotherapy. In clinical practice, there is no evidence that topical indomethacin significantly inhibits the inflammatory response to cryotherapy.

Topics: Administration, Topical; Adolescent; Adult; Child; Clobetasol; Cryotherapy; Dermatitis; Double-Blind Method; Edema; Erythema; Female; Humans; Indomethacin; Male; Middle Aged; Postoperative Complications; Skinfold Thickness; Warts

We studied the effectiveness of clobetasol propionate ointment 0.05% in experimentally induced Rhus dermatitis. Clobetasol rapidly decreased the vesiculation at each treated site, although the effect was most prominent at the site to which clobetasol was applied the earliest, that is, at 12 hours after exposure to Rhus extract. On the basis of this experimental model, clobetasol propionate ointment 0.05% may be effective therapy for naturally occurring Rhus dermatitis.

Topics: Adult; Clobetasol; Dermatitis, Toxicodendron; Edema; Erythema; Female; Humans; Male; Ointments; Skin Tests

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clobetasol; Edema; Exanthema; Glucocorticoids; Humans; Leg; Lung Neoplasms; Male; Pemetrexed; Prednisolone; Treatment Outcome

Topics: Abdomen; Amoxicillin-Potassium Clavulanate Combination; Anti-Inflammatory Agents; Benzimidazoles; Carnitine; Clobetasol; Dermatitis; Edema; Erythema; Female; Humans; Injections, Subcutaneous; Keratosis; Lipolysis; Mesotherapy; Middle Aged; Peptides; Phosphatidylcholines; Piperidines; Prednisone; Subcutaneous Fat; Thigh

Nanostructured lipid carrier (NLC)-based gel was developed as a potential topical system for clobetasol propionate (CP) topical delivery for the treatment of eczema. The characterizations of the prepared NLC formulation for topical application on the skin were assessed by means of morphology (SEM), particle size distribution, zeta potential analysis, drug entrapment efficiency, and in vitro drug release studies to select the optimized NLC formulation. The optimized NLC formulation encompasses particle size of 137.9 nm with -20.5 mV zeta potential and 0.224 polydispersity index which indicates good stability of NLC dispersion. NLC formulation showed a good entrapment efficiency of 78.5 % ± 0.03 with cumulative in vitro release 85.42 % up to 24 h. The optimized NLC formulation was suitably gelled and characterized for rheology, drug content, ex vivo drug permeation studies, and drug release kinetics studies. The permeation study revealed that the permeability parameters like steady-state flux (Jss), permeability coefficient (Kp), and enhancement ratio were significantly higher for NLC-based gel formulation as compared to marketed formulation of clobetasol propionate. The value of r (2) (Korsmeyer-Peppas equation) indicated good linearity showing anomalous (non-Fickian) diffusion viz. drug release is controlled by more than one process, i.e., superposition of both phenomenon, the diffusion controlled as well as swelling controlled release. The anti-inflammatory activity of NLC gel via paw oedema technique showed a rapid onset of action, as well as a prolonged duration of action as compared with the marketed gel.

Topics: Animals; Carrageenan; Clobetasol; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Drug Stability; Edema; Gels; Lipids; Male; Nanostructures; Particle Size; Permeability; Rats; Rheology; Skin; Skin Absorption; Surface Properties

A massive extravasation of pegylated-liposomal doxorubicin (Doxil) accidentally occurred, affecting the right forearm of a 54-year-old woman with metastatic ovarian cancer who was receiving an intravenous infusion of the drug. In accordance with the institutional guidelines for vesicant drugs, a corticosteroid preparation was immediately injected subcutaneously into the surrounding tissues. Clobetasol propionate and an ice pack were then topically applied to the affected region. There were no serious complications at the extravasation site, such as tissue necrosis or severe pain, and only a transient erythema of the skin and desquamation remained after 2 months.

Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibiotics, Antineoplastic; Clobetasol; Doxorubicin; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Forearm; Glucocorticoids; Humans; Hypothermia, Induced; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Treatment Outcome

Easily applicable water-specific instruments measuring local oedema in skin are not available. The aim of this study is to demonstrate quantitative assessment of skin oedema with the dielectric technique by measuring increase of skin water content related to sodium lauryl sulphate (SLS)-induced irritant contact dermatitis.. Irritant skin reaction and resulting oedema were induced by an irritant patch test on volar forearms in 12 healthy volunteers with the application of 1% SLS for 6 h. After occlusion the volunteers were divided into two groups: the patch test site of group I (six volunteers) received no treatment other than a base cream for the skin reaction, while for group II (six volunteers) a strong corticosteroid (clobetasol propionate) was applied on the irritant skin. During a follow-up of 72 h, erythema was scored visually, and irritant-induced oedema was measured with a novel water-specific instrument MoistureMeter-D.. In the untreated irritant skin, a maximum increase of 45% in skin water content was found at 10 h postocclusion and water content was still elevated at 72 h. With these persons, the degree of oedema agreed well with the ultrasound-measured skin thickness (P=0.053). In the corticosteroid-treated skin, an increase of 8% in water content was measured during 72 h but there was no correlation between oedema and skin thickness. There was no correlation between erythema and oedema in untreated or corticosteroid-treated skin.. The new instrument can easily be applied for noninvasive quantitative evaluation of local oedema and fluid retention in irritant-exposed skin.

Topics: Adult; Anti-Inflammatory Agents; Body Water; Clobetasol; Dermatitis, Irritant; Edema; Electrochemistry; Erythema; Humans; Skin; Skin Diseases; Sodium Dodecyl Sulfate; Surface-Active Agents; Ultrasonography

Previous studies have shown the antidotal efficacy of topical iodine at 15 and 30 min post-exposure to sulfur mustard (SM). Here we demonstrate efficacy at longer intervals (20, 30, 45, and 60 min, respectively, for data) using an improved topical povidone-iodine preparation termed N66, which contains steroidal and non-steroidal anti-inflammatory agents. In the mouse, N66 reduced severity of ear edema by 43, 47, 44, and 36%; ear epidermal ulceration by 74, 58, 45, and 58%; and epidermal necrosis by 54, 34, 26, and 31% at the respective time points. A similar effect was observed with encrustation. The healing marker, grade of acanthotic area, showed dramatic increases of 39.6-, 25.3-, 20.9-, and 22-fold. Severity of the dermal parameters, acute inflammation and dermal necrosis, was reduced by 63, 34, 34, and 38% and 80, 54, 54, and 59%, respectively. In guinea pig skin, topical treatment with N66 45 min post-exposure reduced the SM-induced ulceration area by 75%. The histological parameters subepidermal microblister formation, epidermal ulceration, epidermal necrosis, and encrustation were reduced by 63, 61, 41, and 41%, respectively. The healing marker, grade of acanthotic area, was elevated by 73%. N66 induced a statistically significant reduction in two dermal markers for tissue damage: acute inflammation (33%) and dermal necrosis (48%). Reduced skin damage was also observed in areas adjacent the treated sites. The pharmacologically active components of N66 showed additive effect. These findings suggest that the povidone-iodine preparation combined with anti-inflammatory agents functions as a potent antidote against skin lesions induced by SM at relatively long intervals between exposure and treatment.

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Chemical Warfare Agents; Clobetasol; Disease Models, Animal; Drug Combinations; Ear Diseases; Edema; Guinea Pigs; Male; Mice; Mice, Inbred ICR; Mustard Gas; Piroxicam; Povidone-Iodine; Protective Agents; Skin; Skin Diseases; Skin Irritancy Tests; Time Factors

Orofacial granulomatosis (OFG) is a descriptive term used for granulomatous disorders of the face and oral cavity that may occur for a variety of reasons, some of which result in significant morbidity and mortality. Although rarely, a granular enlargements of the gingiva may be the first clinical manifestation of OFG, preceding other local or systemic manifestations.. We will report a case of OFG that showed an atypical and monosymptomatic onset with a generalized hyperplastic gingivitis that preceded other facial and mucosal features by several weeks.. Considering the variable clinical onset of OFG and its apparent increase in incidence, we emphasize that in some cases, the periodontologist, as first consulted health care professional, plays an important role to detect this disorder. Early diagnosis of OFG is a crucial step to prevent and cure its unsightly sequelae and sometimes avoid progression of systemic potentially life-threatening OFG-related diseases.. Thus, when none of the common causes of gingival enlargement can be detected, OFG diagnosis should be suspected.

Topics: Adult; Anti-Inflammatory Agents; Cheilitis; Clobetasol; Diagnosis, Differential; Disease Progression; Edema; Face; Female; Giant Cells; Gingival Hyperplasia; Glucocorticoids; Granuloma; Humans; Mouth Diseases; Triamcinolone

Clobetasol-17-propionate (CP), a synthetic glucocorticoid (GC), reduced skin thickness in rats. Both the subcutaneous injection and topical applications of RU 486 counteracted CP-induced reduction in skin thickness. Topical application of the CP cream completely inhibited the ear edema produced by croton oil. A less potent GC, hydrocortisone-17-butyrate, also inhibited ear edema. This antiinflammatory effect was not abolished by the subcutaneous injection or topical application of RU 486. These observations suggest that GC-induced skin atrophy is mediated by glucocorticoid receptors (GRs), while the inhibition of croton oil-induced inflammation by GC is primarily related to the direct effects of GC, which are not mediated by GRs. Our findings suggest that RU 486 inhibits the atrophogenic effect of GCs without interfering with their antiinflammatory effect. Dissociation of antiinflammatory and atrophogenic activity of GC seems favorable in treating inflammatory skin diseases lacking epidermal proliferation.

Topics: Animals; Anti-Inflammatory Agents; Atrophy; Clobetasol; Croton Oil; Dexamethasone; Ear Diseases; Edema; Glucocorticoids; Ligands; Male; Mifepristone; Rats; Rats, Wistar; Receptors, Glucocorticoid; Skin

Topics: Administration, Topical; Betamethasone; Clobetasol; Cryosurgery; Edema; Humans; Inflammation; Postoperative Complications

The effect of topical clobetasol propionate and a 1% topical indomethacin gel which could inhibit UV erythema was measured on anthralin inflammation by change in skin-fold thickness and erythema. The time course of the inflammatory oedema and erythema were different, as was their response to the drugs studied. The oedema of anthralin inflammation was completely inhibited by clobetasol propionate but the erythemal response showed a small and non-significant reduction. Indomethacin had no effect on anthralin oedema but produced a small but significant reduction in erythema in the first 24 h after anthralin application. These results suggest that either anthralin inflammation is not due to production of prostenoids, or that if it is, it occurs by other than the classical enzymic pathway.

Topics: Adult; Aged; Anthracenes; Anthralin; Betamethasone; Clobetasol; Dermatitis, Contact; Edema; Erythema; Female; Humans; Indomethacin; Male; Middle Aged; Skin Diseases; Ultraviolet Rays